Integer Holdings Highlights 2025 Results, Tightens 2026 Outlook

An announcement from Integer Holdings ( (ITGR) ) is now available.

For the fourth quarter and full year ended Dec. 31, 2025, Integer reported solid topline growth and notably stronger non-GAAP profitability, underscoring successful execution on higher‑growth product ramps and recent acquisitions. Sales rose 5% in the fourth quarter and 8% for the year, with adjusted EPS up 23% in Q4 and 21% for 2025, even as GAAP net income for the year declined on higher costs and restructuring charges; leverage increased to 3.0 times adjusted EBITDA as debt rose to fund deals and buybacks.

Cardio & Vascular remained the main growth engine with double‑digit gains, while Cardiac Rhythm Management & Neuromodulation was mixed and Other Markets shrank due to a previously announced exit from portable medical products. Integer also accelerated capital returns, repurchasing about $50 million of stock in 2025 and announcing an additional $50 million accelerated share repurchase, while 2026 guidance calls for roughly flat sales and modestly softer adjusted earnings ahead of a planned return to above‑market organic growth in 2027.

Integer also accelerated capital returns, repurchasing about $50 million of stock in 2025 and announcing an additional $50 million accelerated share repurchase under its existing authorization, to be financed with cash and credit facility borrowings. For 2026, the company tightened its outlook around prior guidance, projecting roughly flat sales versus 2025 but mid‑single‑digit swings in adjusted operating income and EPS, while management reiterated expectations to resume 200 basis points above‑market organic sales growth in 2027, signaling confidence in its pipeline and long‑term value creation strategy.

The most recent analyst rating on (ITGR) stock is a Hold with a $92.00 price target. To see the full list of analyst forecasts on Integer Holdings stock, see the ITGR Stock Forecast page.

Spark’s Take on ITGR Stock

According to Spark, TipRanks’ AI Analyst, ITGR is a Neutral.

Integer Holdings’ overall score is driven by strong financial performance and positive corporate events. However, technical indicators suggest bearish momentum, and valuation metrics indicate limited upside potential. Earnings call insights reveal near-term challenges, impacting the overall outlook.

To see Spark’s full report on ITGR stock, click here.

More about Integer Holdings

Integer Holdings Corporation is a leading contract development and manufacturing organization serving the medical technology sector, with a portfolio focused on Cardio & Vascular devices, Cardiac Rhythm Management and Neuromodulation products, and other specialty medical markets. The company has been expanding through acquisitions, such as Precision Coating and VSi Parylene, while also exiting certain portable medical lines to refine its market focus.

For the fourth quarter and full year ended Dec. 31, 2025, Integer reported solid topline growth and notably stronger non-GAAP profitability, underscoring successful execution on higher‑growth product ramps and recent acquisitions. Sales rose 5% in the fourth quarter and 8% for the year, with adjusted EPS up 23% in Q4 and 21% for 2025, even as GAAP net income for the year declined on higher costs and restructuring charges; leverage increased to 3.0 times adjusted EBITDA as debt rose to fund deals and buybacks. Cardio & Vascular remained the main growth engine with double‑digit gains, while Cardiac Rhythm Management & Neuromodulation was mixed and Other Markets shrank due to a previously announced exit from portable medical products.

Integer also accelerated capital returns, repurchasing about $50 million of stock in 2025 and announcing an additional $50 million accelerated share repurchase under its existing authorization, to be financed with cash and credit facility borrowings. For 2026, the company tightened its outlook around prior guidance, projecting roughly flat sales versus 2025 but mid‑single‑digit swings in adjusted operating income and EPS, while management reiterated expectations to resume 200 basis points above‑market organic sales growth in 2027, signaling confidence in its pipeline and long‑term value creation strategy.

Average Trading Volume: 676,284

Technical Sentiment Signal: Hold

Current Market Cap: $3.07B

Find detailed analytics on ITGR stock on TipRanks’ Stock Analysis page.